Protagonist Therapeutics Showcases Lasting Success for New Oral Psoriasis Pill
Newark, Saturday, 28 March 2026.
Protagonist Therapeutics revealed strong one-year data for ICOTYDE. As the first oral pill of its kind, this FDA-approved treatment is poised to disrupt the lucrative injectable psoriasis market.
Clinical Efficacy and the Path to Disruption
On March 28, 2026, Protagonist Therapeutics unveiled one-year Phase 3 data for ICOTYDE (icotrokinra) at the American Academy of Dermatology (AAD) Annual Meeting [1]. The data from the ICONIC-ADVANCE 1 and 2 trials indicated durable rates of complete skin clearance through 52 weeks of treatment for patients with moderate-to-severe plaque psoriasis [1]. Furthermore, the studies demonstrated that the percentage of patients achieving PASI 100—a clinical measure of completely clear skin—increased between week 24 and week 52 [1]. The clinical program also highlighted strong efficacy in younger demographics; the ICONIC-LEAD trial showed that nearly 60% of adolescent patients achieved completely clear skin at the one-year mark, with 86% reaching a PASI 90 response and 92% maintaining that response from week 24 to week 52 [1].
A Lucrative Partnership with Johnson & Johnson
The commercialization of ICOTYDE is backed by pharmaceutical giant Johnson & Johnson, stemming from a license and collaboration agreement established with Janssen Biotech in 2017 [1]. Following the drug’s early March 2026 approval by the U.S. Food and Drug Administration (FDA) for adults and pediatric patients aged 12 and older weighing at least 40 kilograms, Protagonist Therapeutics is set to receive a $50 million milestone payment [1][2]. Beyond this immediate capital injection, Protagonist is eligible for up to $580 million in additional milestone payments and will collect tiered royalties ranging from 6% to 10% on worldwide net sales [1].
Market Reaction and Executive Moves
Wall Street has responded favorably to the drug’s earlier-than-expected FDA approval and its potential market disruption. Analysts from several major financial institutions have revised their price targets upward for Protagonist Therapeutics; Jefferies raised its target to $121, Barclays to $119, Truist Securities to $110, and Clear Street to $104 [3]. The consensus rating for the company stands at a Moderate Buy, supported by 13 buy ratings, one hold, and one sell, with an average price target of $107.31 [4]. Over the past year, Protagonist’s shares have surged by 104%, pushing the company’s market capitalization to $6.32 billion [3][4]. On March 27, 2026, the stock closed at $98.97, though it edged up to $99.92 in extended trading [4].